Translational Lung Cancer Research

Papers
(The H4-Index of Translational Lung Cancer Research is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Contrast-enhanced CT and PET-CT characteristics of primary tracheal lymphoepithelioma-like carcinoma: case series70
Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review64
Pushing the boundaries of minimally invasive surgery51
Tackling the challenge of brain involvement in driver-negative non-small cell lung cancer50
Metachronous development of L858R and T790M EGFR mutations following ALK inhibitor therapy in stage IV lung adenocarcinoma: a case report42
PFKP confers chemoresistance by upregulating ABCC2 transporter in non-small cell lung cancer41
Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors39
End-to-side anastomosis in complex tracheal resection and reconstruction: a case series study33
The epidemic of malignant mesothelioma in China: a prediction of incidence during 2016–203029
Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy29
Long-term survival after combination therapy with atezolizumab in a patient with small-cell lung cancer: a case report27
Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer27
Menstrual factors, reproductive history, and risk of lung cancer: a multi-center population-based cohort study in Chinese females27
Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer26
Real-time digital polymerase chain reaction (PCR) as a novel technology improves limit of detection for rare allele assays25
Evaluation of gut leakage and bacterial translocation as efficacy biomarkers of immunotherapy in advanced non-small cell lung cancer (NSCLC)25
Microbiota modulate lung squamous cell carcinoma lymph node metastasis through microbiota-geneset correlation network25
Discrepancies in PD-L1 expression, lymphocyte infiltration, and tumor mutational burden in non-small cell lung cancer and matched brain metastases24
Predictive value of perioperative carcinoembryonic antigen changes for recurrence in non-small cell lung cancer24
Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?24
Can circulating tumor DNA guide treatment de-escalation in metastatic lung adenocarcinoma harboring actionable genomic alterations?24
Molecular mechanism and clinical outcome of non-small cell lung cancer patients with high BRAF expression23
KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer23
0.055339097976685